ALLUVI: A DEEP DIVE INTO THE MEDICATION'S POTENTIAL

Alluvi, initially dubbed LY3414901, represents a significant advancement in metabolic management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable effectiveness in early trial data, with substantial reduction